Iovance Biotherapeutics Sees Unusually High Options Volume (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was the recipient of some unusual options trading on Thursday. Stock investors bought 28,173 call options on the company. This represents an increase of approximately 70% compared to the average volume of 16,565 call options.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. UBS Group lifted their price objective on shares of Iovance Biotherapeutics from $4.00 to $7.00 and gave the company a “neutral” rating in a research note on Thursday, August 20th. The Goldman Sachs Group began coverage on shares of Iovance Biotherapeutics in a report on Thursday, September 24th. They issued a “buy” rating and a $15.00 price target for the company. Citizens Jmp lifted their price target on shares of Iovance Biotherapeutics from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Wells Fargo & Company boosted their target price on shares of Iovance Biotherapeutics from $14.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, September 30th. Finally, Mizuho increased their price target on Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Iovance Biotherapeutics has an average rating of “Moderate Buy” and a consensus target price of $13.20.

Iovance Biotherapeutics News Summary

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported a 24.6% objective response rate in 69 patients with non-squamous mNSCLC, consistent with previously disclosed results. The company said the data support a planned supplemental biologics license application for lifileucel in this indication in 2027. Iovance Updated IOV-LUN-202 Results
• Positive Sentiment: Response rates were substantially higher in selected populations: 43.3% for patients with KRAS wild-type disease versus 11.4% for KRAS-mutant disease, while a novel biomarker-enriched subgroup achieved a 59.1% response rate. Iovance plans to begin the registrational-intent POSITIVITY study in November 2026. Iovance Precision TIL Strategy
• Positive Sentiment: The company’s precision TIL strategy could help identify patients most likely to benefit from lifileucel and expand the potential use of its tumor-infiltrating lymphocyte platform beyond advanced melanoma. Positive Lifileucel Data and Precision TIL Strategy
• Neutral Sentiment: Analysts were positioned for a potential earnings beat, while unusually heavy call-option buying indicated some traders were expecting near-term upside. These signals were overshadowed by the clinical-data reaction. Iovance Earnings Expectations
• Negative Sentiment: Investors treated the updated lung-cancer readout as disappointing or less compelling than hoped, sending the stock sharply lower. The overall 24.6% response rate and the pronounced gap between KRAS subgroups raised concerns about the breadth of benefit in the broader mNSCLC population. Iovance Stock Reaction to Lung Cancer Data

Hedge Funds Weigh In On Iovance Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in IOVA. Compass Financial Management LLC bought a new stake in Iovance Biotherapeutics during the 3rd quarter worth $37,000. Valley National Advisers Inc. acquired a new stake in Iovance Biotherapeutics in the third quarter worth $38,000. Root Financial Partners LLC acquired a new position in shares of Iovance Biotherapeutics during the third quarter worth approximately $44,000. Provenance Wealth Advisors LLC acquired a new position in Iovance Biotherapeutics during the 3rd quarter valued at about $61,000. Finally, GK Wealth Management LLC purchased a new stake in shares of Iovance Biotherapeutics in the third quarter valued at about $107,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

Iovance Biotherapeutics Stock Down 11.3%

NASDAQ IOVA traded down $1.08 during trading on Friday, reaching $8.48. 31,139,366 shares of the stock traded hands, compared to its average volume of 13,862,792. Iovance Biotherapeutics has a fifty-two week low of $1.76 and a fifty-two week high of $15.37. The stock’s 50-day moving average price is $11.37 and its 200 day moving average price is $5.82. The firm has a market cap of $3.84 billion, a price-to-earnings ratio of -11.62 and a beta of 0.76.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%. The business had revenue of $99.31 million for the quarter, compared to analysts’ expectations of $87.83 million. During the same quarter in the previous year, the business posted ($0.33) EPS. Iovance Biotherapeutics’s revenue for the quarter was up 65.7% on a year-over-year basis. Analysts anticipate that Iovance Biotherapeutics will post -0.45 EPS for the current fiscal year.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.